The special immunotherapy edition of Perspective magazine is live

Blue Latitude Health|19th May 2016

As a creative marketing consultancy, we have a unique perspective on the challenges facing the broad range of stakeholders in the healthcare and pharma industry. As such, we've created this magazine to explore those challenges in depth from a variety of viewpoints.

In this supplementary issue, we’re taking a special look at immunotherapies, and more specifically, the growing buzz around “immuno-oncology” therapies. At the time of publication, Blue Latitude Health have worked with four of the eight immunotherapies currently approved by the FDA, so we’ve pooled our expertise across the different capabilities to give you a clear view on the fourth pillar of care in oncology.

 

The immunotherapy special issue covers:

  • Immunology in oncology as a therapy area – what it is, how it works, and where it’s heading from a medical and commercial point of view.
  • Key insights around positioning immuno-oncology products based on our hands-on experience working in this area.
  • What new immunotherapies in oncology mean for cancer patients and the doctors who would prescribe them, and in turn, what that means for pharma.
  • The immuno-therapy patient experience as a customer journey.

 

Click the button below to enter your details and receive your digital copy.

How Medisafe is using AI to improve patient adherence

Dina Patel|14th February 2019

Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence.

read more

Downloadable Pack: Understanding Multiple Sclerosis

Blue Latitude Health, Guest Blogger|6th February 2019

Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry.

read more

Six factors that drive a multiple sclerosis patient's choice of disease-modifying therapy

Guest Blogger|1st February 2019

MS advocate Trishna Bharadia explains the numerous factors that lead patients to choose a disease-modifying therapy, including the important considerations healthcare professionals and pharma often forget.

read more